Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PR
10 hours ago
- #ARPI resistance
- #AR-V7 localization
- #mCRPC prognosis
- Nuclear AR-V7 in CTCs predicts poor response, progression-free survival (PFS), and overall survival (OS) to androgen receptor pathway inhibitors (ARPIs) in metastatic castration-resistant prostate cancer (mCRPC).
- Cytoplasmic-only AR-V7 is more common than nuclear AR-V7 and is associated with poor PFS and intermediate PSA response and OS outcomes, expanding the definition of AR-V7-positive status.
- Assessing both nuclear and cytoplasmic AR-V7 in circulating tumor cells (CTCs) may improve risk stratification and guide treatment decisions by identifying patients less likely to benefit from ARPI therapy.